Aspira Women's Health Reports Officer and Director Changes

Ticker: AWHL · Form: 8-K · Filed: 2025-03-19T00:00:00.000Z

Sentiment: neutral

Topics: leadership-change, officer-appointment, director-election, compensation

Related Tickers: AWH

TL;DR

Aspira Women's Health (AWH) filed an 8-K for leadership and compensation changes effective March 15.

AI Summary

Aspira Women's Health Inc. filed an 8-K on March 19, 2025, reporting changes as of March 15, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the compensatory arrangements are expected to be elaborated within the filing's exhibits.

Why It Matters

Changes in key leadership and officer compensation can signal shifts in company strategy, operational focus, or financial health, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in directors and officers, especially if related to compensation, can indicate internal shifts that may affect the company's direction and stability.

Key Players & Entities

FAQ

What specific officer positions were affected by the changes reported in the 8-K?

The filing indicates the appointment of certain officers, but the specific positions are detailed in the exhibits.

Were there any director departures or new director elections?

Yes, the filing explicitly mentions the departure of directors or certain officers and the election of directors.

What is the effective date of the reported changes?

The earliest event reported is dated March 15, 2025.

Does the filing detail the compensatory arrangements for the officers?

Yes, the filing covers compensatory arrangements of certain officers, with specifics likely found in the accompanying exhibits.

What is the SIC code for Aspira Women's Health Inc.?

The Standard Industrial Classification (SIC) code for Aspira Women's Health Inc. is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.

From the Filing

0001493152-25-010933.txt : 20250319 0001493152-25-010933.hdr.sgml : 20250319 20250319170009 ACCESSION NUMBER: 0001493152-25-010933 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250315 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250319 DATE AS OF CHANGE: 20250319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 25753546 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm false 0000926617 0000926617 2025-03-15 2025-03-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549       FORM 8-K       CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2025       Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-34810   33-0595156 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   12117 Bee Caves Road Building III Suite 100     Austin , Texas   78738 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 512 519-0400     (Former Name or Former Address, if Changed Since Last Report)       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWH   The Nasdaq Stock Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain

View on Read The Filing